- Home
- UIS vs LRMR Comparison
UIS vs LRMR Comparison
Compare UIS & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UIS
- LRMR
- Stock Information
- Founded
- UIS 1942
- LRMR N/A
- Country
- UIS United States
- LRMR United States
- Employees
- UIS N/A
- LRMR N/A
- Industry
- UIS EDP Services
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- UIS Technology
- LRMR Health Care
- Exchange
- UIS Nasdaq
- LRMR Nasdaq
- Market Cap
- UIS 474.3M
- LRMR 426.9M
- IPO Year
- UIS N/A
- LRMR N/A
- Fundamental
- Price
- UIS $6.53
- LRMR $4.01
- Analyst Decision
- UIS
- LRMR Strong Buy
- Analyst Count
- UIS 0
- LRMR 8
- Target Price
- UIS N/A
- LRMR $19.63
- AVG Volume (30 Days)
- UIS 706.2K
- LRMR 1.1M
- Earning Date
- UIS 02-19-2025
- LRMR 10-30-2024
- Dividend Yield
- UIS N/A
- LRMR N/A
- EPS Growth
- UIS N/A
- LRMR N/A
- EPS
- UIS N/A
- LRMR N/A
- Revenue
- UIS $2,020,600,000.00
- LRMR N/A
- Revenue This Year
- UIS $0.92
- LRMR N/A
- Revenue Next Year
- UIS $2.90
- LRMR N/A
- P/E Ratio
- UIS N/A
- LRMR N/A
- Revenue Growth
- UIS 0.29
- LRMR N/A
- 52 Week Low
- UIS $3.32
- LRMR $3.01
- 52 Week High
- UIS $8.93
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- UIS 39.54
- LRMR 25.50
- Support Level
- UIS $6.48
- LRMR $3.83
- Resistance Level
- UIS $7.08
- LRMR $6.91
- Average True Range (ATR)
- UIS 0.47
- LRMR 0.57
- MACD
- UIS -0.16
- LRMR -0.22
- Stochastic Oscillator
- UIS 2.04
- LRMR 25.64
About UIS Unisys Corporation New
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides solutions that transform digital workplaces securely and create exceptional end-user experiences. CA&I provides digital platform, applications and infrastructure solutions. ECS provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.